{'fraction_non_alphanumeric': 0.01413760603204524, 'fraction_numerical': 0.007540056550424128, 'mean_word_length': 5.321428571428571, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Pharmacogenomics Based Study for Liraglutide And Metfromin (PCOS Drugs) Efficacy In Populations Across The Globe

Polycystic ovary syndrome (PCOS) is an endocrine disorder which affects about 6-10% women across the world especially in the reproductive stage. Liraglutide an analog to GLP-1 and metformin which is an AMPK agonist lower blood glucose concentration in overweight or obese PCOS patients and thus used for reducing weight and restoring ovulation. However genetic variability leads to inter-individual differences in effectiveness of these drugs leading to clinical unpredictability which is mainly attributed to single nucleotide polymorphisms (SNPs) in targets of these drugs. This study is aimed at finding drug response for diabetic symptoms in PCOS in certain populations based on SNP data from 1000Genomes and gnomAD projects, thus finding regions of strong and weak respondents to these drugs which will further help clinicians in deciding the dose and type of drug to be given to people in the countries or regions depending on SNP frequency.